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Abstract— An efficient process for the discovery of inhibitors of DDAH enzymes, without the requirement for high throughput 
screening, is described. Physicochemical filtering of a 308,000 compound library according to drug likeness followed by reciprocal 
nearest neighbor selection produced a representative subset of 35,000 compounds.  Virtual screening on a dual processor PC using FlexX, 
followed by biological screening identified two hit series. Similarity searches of commercial databases and chemical re-synthesis of pure 
compounds resulted in SR445 as an inhibitor of Pseudomonas aeruginosa DDAH at 2 µM. 
The pentein superfamily of proteins (Figure 1a) is 
characterized by a propeller like arrangement of five 
αββαβ units forming a narrow channel with a central 
negatively charged core.1, 2 This elegant structure is 
ideal for recognition of the guanidinopropyl side chain 
of the amino acid arginine: its main biological function 
in the guanidine modifying enzyme (GME) branch of 
the superfamily. GMEs contain a conserved triad of His, 
Asp, and Cys amino acids which serve to catalyze a 
range of hydrolysis and transferase reactions on the 
arginine or, in the case of DDAH, the methyl arginine 
side chain (Figure 1b). The biological functions of this 
family are very diverse,2 not only allowing metabolic 
reactions on simple arginine derivatives but also, in the 
case of the protein arginine deiminases (PADs), able to 
function as molecular switches for transcription by 
citrullination of arginine side chains on histones.3 
Mammalian DDAH functions to control ADMA levels 
(a cardiovascular risk factor) and can modulate the nitric 
oxide pathway with its pivotal role in endothelial cell 
function.4, 5 Significantly DDAH may also participate in  
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protein regulation and DDAH 2 has been shown to 
increase transcription of the cancer promoting cytokine 
VEGF6 (Figure 1). Pseudomonas aeruginosa (Pa) is a 
pathogen linked to chronic lung infections in cystic 
fibrosis7 and PaDDAH is a possible factor involved in 
pathogenicity.8 The discovery of inhibitors of DDAH 
and the wider pentein family is therefore of 
considerable interest (Figure 2) and both competitive 1, 
2 and irreversible 3.4.5 inhibitors have been reported.3, 
9-12 
 
We have previously described substrate based 
inhibitors9 of mammalian DDAH such as 1 (SR291), 
however we required access to inhibitors of better 
potency and different chemical structural types. The 
availability of the PaDDAH crystal structure, allowed 
us to consider virtual screening as an approach to the 
discovery of new inhibitors. Virtual screening has many 
potential advantages: lower cost, higher speed and 
lower resource requirements make it ideally suited to an 
academic research group. We therefore initiated an 
approach based on physicochemical filtering, virtual 
screening and hit analysis to identify inhibitors of 
PaDDAH utilizing the crystal structure.13  
 
 
 
 
Starting with a database of 308,000 commercially 
available compounds,  we initially employed a series 
of filters to remove about 48,000 non-druglike  
compounds and reactive molecules (Figure 3). This first 
step is divided into a structural filter  (see 
supplementary data) which removes non-drug-like 
compounds and those with undesirable atoms/functional 
groups and a properties filter  that passes only lead-
like compounds. All filtering was implemented with 
scripts written in the Sybyl programming language 
(SPL). After this first step the number of compounds in 
the databases was reduced to ~260k. A reciprocal 
nearest neighbor  (RNN) packing algorithm was then 
utilized to generate a diverse, subset of
14
15,16
17,18
19, 20
21
 compounds such 
that clusters of similar compounds in the original 
database were represented by small groups of 
compounds (not singletons) in the subset. In this way a 
cluster containing actives is better represented in the 
subset.  The subset of 35,000 two dimensional 
structures was then converted into 3D using Concord  
and minimized with the MMFF94 force field. In the 
final step the MMFF94 charges were replaced with 
formal charges for input to the docking program FlexX. 
The PaDDAH structure (pdb: 1h70) was manipulated by 
restoring the Cys249, adding hydrogens and Kollman 
atom charges then minimized using the Amber Force 
Field (version 7.0). Citrulline was left in place during 
the minimization to prevent collapse of the active site 
and was then removed. Virtual docking was conducted 
using FlexX.  FlexX cuts ligands into fragments at 
rotatable bonds and places a base fragment into the 
active site, the ligand is then reformed and the energy 
calculated using Bohm’s function. The dimethylarginine 
binding pocket site was defined accurately using the 
Sybyl/Flexx interface (Leu18, Asp 60, Phe63, Asp66, 
Glu65, Arg85, Glu114, Arg132, Leu161, His162, 
Ile243, C249). 
22
23
24
 
The top 2,000 successfully docked compounds were 
ranked with the CScore scoring function. The highest 
scoring 200 molecules were visually inspected to ensure 
that the docking algorithm had placed them in the 
binding pocket with at least one hydrogen bond between 
the protein and the ligand. Of these 109 structures, 90 
were available for supply and these were screened, 
using a simple colorimetric assay (see supporting 
information). Three actives were identified, compounds 
6, 7 and 8 (Figure 4) representing two chemical 
scaffolds.  
 
About 30% of the original screening set exhibited poor 
solubility precluding accurate IC50 determination. The 
activity around the active scaffolds was probed by the 
purchase of 20 additional analogues identified using 
similarity searches on the active hits based on Unity 
fingerprints and a Tanimoto score of >80%. 
 
Re-synthesis to provide pure authentic samples was a 
key part of the hit analysis and the general synthesis25 is 
shown for compounds 9 and 10 in scheme 1.  If required 
the indole carbaldehydes were N-alkylated followed by 
condensation with the substituted barbituric acids26 to 
provide the target molecules. 
 
The indolylthiobarbituric acid scaffold proved the most 
interesting; the compounds resulting from the similarity 
searches, 9 and 10 (SR445) demonstrated much 
improved activity in the re-synthesised samples with 10 
having an IC50 of 2 µM. This is the most potent 
PaDDAH inhibitor identified to date and is structurally 
distinct from the other inhibitors of both PaDDAH and 
mammalian DDAH (Figure 2). The predicted binding 
mode of 10 (Figure 5), shows insertion into the active 
site of DDAH with the indole moiety taking the place of 
the arginine side-chain. 
 
This study highlights the advantages of virtual 
screening, allowing academic laboratories with limited 
manpower and resources to discover protein ligands for 
biological studies. Pre-filtering the database produced a 
representative set amenable to screening on a dual 
processor PC. We cannot yet consider the docking 
process to be very precise.27 Rather docking enriches 
the final biological screening set to increase the chances 
of obtaining an active. The recent disclosures of the 
crystal structures of bovine and human DDAH5, 28 
should allow similar methodology to be applied to the 
discovery of  inhibitors of the mammalian and human 
isoforms.  
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Figure and Scheme Legends 
 
Figure 1. (a) Ribbon diagrams of pentein family proteins PaDDAH and 
PAD4.  (b) DDAH hydrolyses methylated arginines including ADMA a 
cardiovascular risk factor. DDAH2 can increase the expression of VEGF 
through phosphorylation of its transcription factor SP1. 
 
Figure 2. Inhibitors of DDAH and PAD4. 
 
Figure 3.  Filtering, virtual screening, biological testing and hit analysis 
lead to the discovery of micromolar inhibitors of DDAH. 
 
Figure 4. Structures and activity (500 µM) of screening hits (blue) and 
similarity search hits (black). IC50s are of re-synthesized pure samples. 
aInsoluble in buffer. 
Figure 5. Top and side views of predicted binding mode of 10. 
Scheme 1. General synthesis of the indolyl barbiturates. 
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Figure 4. Structures and activity (500 µM) of screening hits (blue) and 
similarity search hits (black). IC50s are of re-synthesized pure samples. 
aInsoluble in buffer. 
 
 
 
 
Scheme 1. General synthesis of the indolyl barbiturates. 
 
 
Figure 5. Top and side views of predicted binding mode of 10. 
 
 
 
